18F-FSPG PET/CT检测到心内转移瘤
本病例报告展示一例非小细胞肺癌患者的心肌和心包转移灶,这些转移灶被生理性18F-FDG心肌摄取所掩盖,而通过研究性PET示踪剂18F-FSPG(靶向谷胱甘肽生物合成通路)得以检出。该病例表明18F-FSPG PET/CT成像具有附加价值。
要点
- 18F-FDG PET/CT因生理性心肌摄取可掩盖心脏转移灶。
- 18F-FSPG靶向谷胱甘肽生物合成通路,可检出被FDG掩盖的心肌和心包转移。
- 本病例显示18F-FSPG PET/CT在肿瘤诊断和再分期中的附加价值。
核心结论
- 本病例表明18F-FSPG PET/CT成像具有附加价值。
研究设计与样本
- 本文为一例非小细胞肺癌患者的病例报告。
主要发现
- 该非小细胞肺癌患者的心肌和心包转移灶被生理性18F-FDG心肌摄取所掩盖,但通过研究性PET示踪剂18F-FSPG检出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/CT imaging is frequently used for cancer diagnosis and restaging as metabolically active cells, including cancer, utilize glucose for proliferation. F-FDG is the most commonly utilized radiopharmaceutical in PET/CT imaging. Limitations of F-FDG imaging include intense physiologic uptake in benign tissues such as the brain and myocardium. We present a case of non-small cell lung cancer with myocardial and pericardial metastases obscured by physiologic F-FDG cardiac uptake but detected with the investigational PET radiotracer (4S)-4-(3-F-fluoropropyl)-L-glutamate (F-FSPG), which targets a pathway associated with glutathione biosynthesis. This case demonstrates the added value of F-FSPG PET/CT imaging.
引用
- Magarik MA, Walker RC, Gilbert J, et al. Intracardiac Metastases Detected by 18F-FSPG PET/CT. Clin Nucl Med. 2018. PMID: 29076915. doi:10.1097/RLU.0000000000001883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。